Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180011
Status:
COMPLETED
Last Update Posted:
2012-02-28
First Post:
2005-09-10
Brief Title:
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
Sponsor:
DiMango Emily MD
Organization:
DiMango Emily MD
Study Overview
Official Title:
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be a randomized placebo controlled double blind study to measure the safety and efficacy of a new injectable asthma medication omalizumab in a group of minority with moderate to severe asthma who are not adequately controlled with use of inhaled or oral steroids Primary endpont will be change in asthma symptom utility index Secondary endpoints will be changes in asthma Quality of life asthma exacerbation rate and lung function over the 12 week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None